DK1117437T3 - Anvendelse af forbindelser, der reducerer alfa2-antiplasmin in vivo, til fremstilling af en sammensætning til behandling af iskæmiske slagtilfælde - Google Patents

Anvendelse af forbindelser, der reducerer alfa2-antiplasmin in vivo, til fremstilling af en sammensætning til behandling af iskæmiske slagtilfælde

Info

Publication number
DK1117437T3
DK1117437T3 DK99948942T DK99948942T DK1117437T3 DK 1117437 T3 DK1117437 T3 DK 1117437T3 DK 99948942 T DK99948942 T DK 99948942T DK 99948942 T DK99948942 T DK 99948942T DK 1117437 T3 DK1117437 T3 DK 1117437T3
Authority
DK
Denmark
Prior art keywords
treatment
antiplasmin
ischemic stroke
vivo
compounds
Prior art date
Application number
DK99948942T
Other languages
English (en)
Inventor
Desire Jose Collen
Nobuo Nagai
Original Assignee
Leuven Res & Dev Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99202004A external-priority patent/EP1062953A1/en
Application filed by Leuven Res & Dev Vzw filed Critical Leuven Res & Dev Vzw
Application granted granted Critical
Publication of DK1117437T3 publication Critical patent/DK1117437T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
DK99948942T 1998-09-29 1999-09-24 Anvendelse af forbindelser, der reducerer alfa2-antiplasmin in vivo, til fremstilling af en sammensætning til behandling af iskæmiske slagtilfælde DK1117437T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98203280 1998-09-29
EP99202004A EP1062953A1 (en) 1999-06-22 1999-06-22 Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
PCT/EP1999/007405 WO2000018436A1 (en) 1998-09-29 1999-09-24 Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke

Publications (1)

Publication Number Publication Date
DK1117437T3 true DK1117437T3 (da) 2007-04-10

Family

ID=26150731

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99948942T DK1117437T3 (da) 1998-09-29 1999-09-24 Anvendelse af forbindelser, der reducerer alfa2-antiplasmin in vivo, til fremstilling af en sammensætning til behandling af iskæmiske slagtilfælde

Country Status (12)

Country Link
US (1) US6946438B1 (da)
EP (1) EP1117437B1 (da)
JP (1) JP4577992B2 (da)
CN (1) CN1191856C (da)
AT (1) ATE349226T1 (da)
AU (1) AU6200599A (da)
CA (1) CA2344317C (da)
DE (1) DE69934595T2 (da)
DK (1) DK1117437T3 (da)
ES (1) ES2276536T3 (da)
HK (1) HK1041449B (da)
WO (1) WO2000018436A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1343903E (pt) * 2000-12-21 2008-02-18 Thrombogenics Nv ''um vector de expressão de levedura e um método de produção de uma proteína recombinante por expressão numa célula de levedura
EP1545588A4 (en) * 2002-07-23 2007-12-05 Ludwig Inst Cancer Res METHOD AND COMPOSITIONS FOR THE ACTIVATION OR INHIBITION OF VEGF-D AND VEGF-C
PL2246417T3 (pl) 2004-04-22 2015-06-30 Grifols Therapeutics Inc Rekombinacyjnie zmodyfikowana plazmina
US8101394B2 (en) 2007-11-29 2012-01-24 Grifols Therapeutics Inc. Recombinantly modified plasmin
UA103771C2 (ru) * 2008-06-04 2013-11-25 Грифолз Терапьютикс Инк. Стрептокиназа, активирующая плазмин, способ и набор для получения плазмина
RU2372086C1 (ru) * 2008-08-06 2009-11-10 Илья Николаевич Медведев СПОСОБ НОРМАЛИЗАЦИИ УРОВНЯ α2 АНТИПЛАЗМИНА ПРИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ С НАРУШЕНИЕМ ТОЛЕРАНТНОСТИ К ГЛЮКОЗЕ
JP5789521B2 (ja) 2009-03-03 2015-10-07 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プラスミノーゲンを製造するための組成物、方法およびキット；ならびにそれから製造されるプラスミン
NZ597452A (en) * 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
EP2753359B1 (en) * 2011-09-06 2018-02-28 Translational Sciences Inc. Serpinf2-binding molecules and methods of use
TWI653981B (zh) * 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
JP2019500426A (ja) 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病網膜症を予防または治療するための方法
CA3008466C (en) 2015-12-18 2023-06-20 Talengen International Limited Method for preventing or treating radiation and chemical damage
EP3395354B1 (en) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
CN106890325A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
WO2017101871A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗心血管病的新方法
EP3395355B1 (en) 2015-12-18 2026-03-04 Talengen International Limited Plasminogen for use in treating cervical erosion
WO2018107701A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种新的降血糖和提高糖耐量的药物
WO2021072404A1 (en) * 2019-10-10 2021-04-15 University Of Kentucky Research Foundation A machine learning algorithm for predicting clinical outcomes and identifying drug targets in ischemic stroke
CN117677715B (zh) * 2021-07-28 2025-09-26 北京沙东生物技术有限公司 一种骨髓瘤生物标志物serpinf2及其应用
CN114736948B (zh) * 2022-06-10 2022-11-08 深圳市帝迈生物技术有限公司 一种α2-抗纤溶酶活性测定试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
US20030017147A1 (en) * 1996-09-20 2003-01-23 Guy L Reed Composition and method for enhancing fibrinolysis

Also Published As

Publication number Publication date
EP1117437B1 (en) 2006-12-27
HK1041449A1 (en) 2002-07-12
ATE349226T1 (de) 2007-01-15
CN1191856C (zh) 2005-03-09
AU6200599A (en) 2000-04-17
ES2276536T3 (es) 2007-06-16
US6946438B1 (en) 2005-09-20
DE69934595T2 (de) 2007-10-04
WO2000018436A1 (en) 2000-04-06
DE69934595D1 (de) 2007-02-08
CN1320045A (zh) 2001-10-31
EP1117437A1 (en) 2001-07-25
HK1041449B (zh) 2005-08-19
JP2002525340A (ja) 2002-08-13
CA2344317A1 (en) 2000-04-06
JP4577992B2 (ja) 2010-11-10
CA2344317C (en) 2012-01-24

Similar Documents

Publication Publication Date Title
AU6200599A (en) Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of acomposition for the treatment of ischemic stroke
MY133996A (en) Compounds for the treatment of ischemia
TR200003011T2 (tr) Yeni dihidropirimidinler.
FR2627696B1 (fr) Nouvelle forme galenique du fenofibrate
BR0215405A (pt) Composições e processos de uso de collajolie
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
TR200001203T2 (tr) Yeni birleşik maddeler
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
PE20020802A1 (es) COMPUESTO DE LACTAMA COMO INHIBIDOR DE LA LIBERACION DEL PEPTIDO ß-AMILOIDE
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
IL153014A0 (en) Barbituric acid analogs as therapeutic agents
ATE429210T1 (de) Orale flüssige zusammensetzungen
DZ2936A1 (fr) Composition nouvelle à libération modifiée pour letraitement du diabète.
ATE368023T1 (de) Hydroxydiphenyletherverbindungen
AU2002220715A1 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
GB0111186D0 (en) Novel compounds
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
IT1293778B1 (it) 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
DE59806371D1 (de) Kontrastmittel für das infarkt- und nekroseimaging
SE9901077D0 (sv) Novel use
NO983530D0 (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
SE9804212D0 (sv) Compounds
SE9801494D0 (sv) Novel use
TR200504091T2 (tr) (7alfa,17alfa)-17-hidroksi-7-metil-19-nor-17-pregn-5(10)-en 20-in-3-on içeren yüksek saflıkta bileşim.
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.